[HTML][HTML] Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
…, M Jeraiby, A Alomaish, O Elrhima, S Qumayi… - Saudi Medical …, 2022 - ncbi.nlm.nih.gov
Objectives: To evaluate hematological parameters and thrombotic profiles of healthy
individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia. Methods: …
individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia. Methods: …
[HTML][HTML] Prevalence of asthenopia and its relationship with electronic screen usage during the covid-19 pandemic in jazan, saudi arabia: a cross-sectional study
I Abuallut, EA Qumayi, AJ Mohana… - Clinical …, 2022 - ncbi.nlm.nih.gov
… Ismail Abuallut, 1 Elham A Qumayi, 2 Azah Jabir Mohana, 3 Norah M Almalki, 2 Majdah
E Ghilan, 2 Fatimah H Dallak, 2 Sarah Mohammed Mahzari, 2 Almoayad Makrami, 4 Amal …
E Ghilan, 2 Fatimah H Dallak, 2 Sarah Mohammed Mahzari, 2 Almoayad Makrami, 4 Amal …
Knowledge and Health Beliefs of Ocular Manifestations, Complications, and Treatment of Sickle Cell Disease in Saudi Arabia: A Cross-Sectional Study
…, OI Daak, AM Alshehri, EA Qumayi… - Hail Journal of Health …, 2022 - journals.lww.com
Background: Sickle cell disease (SCD) remains a common genetically inherited disorder in
Saudi Arabia. While recent advances in SCD treatment have provided new insight into the …
Saudi Arabia. While recent advances in SCD treatment have provided new insight into the …
